Compare UNTY & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | MNPR |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.4M | 531.6M |
| IPO Year | 1997 | 2019 |
| Metric | UNTY | MNPR |
|---|---|---|
| Price | $56.14 | $65.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $59.67 | ★ $97.83 |
| AVG Volume (30 Days) | 37.5K | ★ 165.4K |
| Earning Date | 01-14-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ 35.12 | N/A |
| EPS | ★ 5.27 | N/A |
| Revenue | ★ $121,970,000.00 | N/A |
| Revenue This Year | $24.41 | N/A |
| Revenue Next Year | $11.16 | N/A |
| P/E Ratio | $10.69 | ★ N/A |
| Revenue Growth | ★ 20.98 | N/A |
| 52 Week Low | $36.65 | $21.00 |
| 52 Week High | $57.24 | $105.00 |
| Indicator | UNTY | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 75.28 | 31.27 |
| Support Level | $55.35 | $73.63 |
| Resistance Level | $57.24 | $77.45 |
| Average True Range (ATR) | 1.76 | 5.34 |
| MACD | 0.33 | -1.55 |
| Stochastic Oscillator | 86.16 | 4.01 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. It conducts a traditional and community-oriented commercial banking business and offers services, including personal and business checking accounts, time deposits, money market accounts, regular savings accounts, and others. The company structures its specific services and charges in a manner designed to attract the business of small and medium-sized businesses and professional communities, as well as individuals residing, working, and shopping in its service area. The company engages in a wide range of lending activities and offers commercial, Small Business Administration, consumer, mortgage, home equity, and personal loans.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.